Targeted drug plus standard chemo-immunotherapy for NK/T-cell lymphoma
Part of Cancer clinical trials.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with stage III, IV, or non-nasal extranodal NK/T-cell lymphoma.
- You haven't had any prior cancer treatment for this lymphoma.
- You are in good overall health (able to do most daily activities, no severe heart or bleeding issues).
- Your liver, kidney, and blood tests are within acceptable limits (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This study tests a new medicine called sugemalimab (an immunotherapy that helps your immune system fight cancer) combined with a chemotherapy regimen (PGemOx) for people with a rare type of lymphoma that has come back or not responded to previous treatment. The study could help you see if this combination works better than the placebo (inactive) plus the same chemotherapy.
This trial tests a new drug, selinexor, combined with a lower dose of radiation for people with early-stage extranodal NK/T-cell lymphoma that started in the nose or upper throat. The goal is to see if this combination works well and has fewer side effects.
This study tests a new combination of three drugs (golidocitinib, pegaspargase, and an immune checkpoint inhibitor) as the first treatment for advanced extranodal natural killer/T-cell lymphoma. The goal is to see if this combination can shrink or eliminate the cancer and improve outcomes.
This trial tests a combination of three drugs (selinexor, an anti-PD-1 antibody, and golidocitinib) for patients with relapsed or refractory NKTCL. The goal is to see if this combination can effectively treat the lymphoma and improve outcomes.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.